Stock CLXP.F CYBIN INC.
Add to a list

Cybin Inc. Stock OTC Markets

Stocks

CLXP.F

CA23256X1006

Biotechnology & Medical Research

OTC Markets Traded
End-of-day quote OTC Markets
Other stock markets
 2021-09-01 		5-day change 1st Jan Change
2.630 CAD -6.07% Intraday chart for Cybin Inc. +17.41% +76.51%
08-03 Helus Pharma Names Michael Halstead CEO MT
08-03 Helus Pharma Announces Appointment of Michael Halstead as Chief Executive Officer, Effective August 3, 2026 CI

Valuation: Cybin Inc.

Market Cap 703M 500M 434M 404M 372M 47.52B 710M 4.77B 1.86B 23.76B 1.88B 1.84B 78.71B P/E 2027 *
-3.55x
P/E 2028 * -4.42x
Enterprise Value 267M 190M 165M 153M 141M 18.03B 270M 1.81B 707M 9.01B 712M 696M 29.86B EV / Sales 2027 *
-
EV / Sales 2028 * 9.54x
Free-Float
97.25%
Yield 2027 *
-
Yield 2028 * -
* Estimated data More valuation ratios

Latest news : Cybin Inc.

08-03 Helus Pharma Names Michael Halstead CEO MT
08-03 Helus Pharma Announces Appointment of Michael Halstead as Chief Executive Officer, Effective August 3, 2026 CI
07-27 Wells Fargo Initiates Cybin at Overweight With CA$22.56 Price Target MT
07-21 Helus Pharma Completes Enrollment in Phase 3 Study for Depression Treatment MT
07-21 Helus Pharma Completes Enrollment In APPROACH Phase 3 Pivotal Study Of HLP003 In Adjunctive Treatment Of Major Depressive Disorder CI
06-29 Cybin Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
06-25 Helus Pharma Closes $50 Million Underwritten Offering MT
06-24 Helus Pharma Says Enrollment Tops 86% for Phase 3 HLP003 Trial in Major Depressive Disorder MT
06-24 Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress CI
06-24 Helus Pharma Prices $50 Million Underwritten Offering MT
04-30 Cybin Inc. will Change its Name to Helus Pharma CI
04-28 Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health CI
04-24 FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers Gain MT
More news

Last Transcript: Cybin Inc.

Logo Cybin Inc.
Cybin Inc. - Special Call
03-06
More transcripts

Analysts' recommendations: Cybin Inc.

07-27 Wells Fargo Initiates Cybin at Overweight With CA$22.56 Price Target MT
04-13 TD Cowen Initiates Coverage on Cybin With Buy Rating MT
02-02 Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target MT
23-11-17 HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating MT
23-08-15 Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating MT
More recommendations

Press Releases: Cybin Inc.

08-03 Helus Pharma Appoints Michael Halstead as Chief Executive Officer GL
07-21 A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening AQ
07-21 Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates AQ
07-21 Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule GL
07-17 Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time AQ
More press releases

News in other languages: Cybin Inc.

02-11 Helus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
02-11 Helus Pharma nombra a Michael Cola como director ejecutivo para liderar su próxima etapa de crecimiento y ejecución
02-11 Helus Pharma ernennt Michael Cola zum Chief Executive Officer für die Leitung der nächsten Skalierungs- und Durchführungsphase
24-03-14 Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3
24-03-14 Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3
More news

Managers and Directors: Cybin Inc.

Manager TitleAgeSince
Eric So CEO
 Chief Executive Officer 51 2025-09-01
Paul Glavine COO
 Chief Operating Officer 37 2016-10-12
Michael Halstead CEO
 Chief Executive Officer 53 2026-08-02
Director TitleAgeSince
Eric So CHM
 Chairman 51 2020-11-04
Paul Glavine BRD
 Director/Board Member 37 2016-10-12
Eric Hoskins BRD
 Director/Board Member 65 2020-11-04
More insiders

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
CYBIN INC. Stock Cybin Inc.
-6.07%+17.41% - - 500M
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+10.00%+13.39%+51.99%+83.45% 56.7B
ARGENX SE Stock argenx SE
+0.80%-7.82%+24.61%+60.00% 51.97B
BIONTECH SE Stock BioNTech SE
-0.98%+0.29%-14.90%-14.35% 23.33B
INSMED INCORPORATED Stock Insmed Incorporated
+0.30%-5.71%-9.15%+345.82% 21.34B
GENMAB A/S Stock Genmab A/S
+1.73%-1.57%+35.40%-28.62% 17.44B
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
+4.29%+1.67%+201.24%+344.48% 14.77B
EXELIXIS, INC. Stock Exelixis, Inc.
+1.71%+0.34%+50.30%+169.75% 13.84B
ARROWHEAD PHARMACEUTICALS, INC. Stock Arrowhead Pharmaceuticals, Inc.
+4.16%+4.75%+462.40%+177.20% 12.12B
MADRIGAL PHARMACEUTICALS, INC. Stock Madrigal Pharmaceuticals, Inc.
+5.30%-7.93%+67.97%+162.62% 11.14B
Average +2.12%-0.63%+96.65%+144.48% 24.74B
Weighted average by Cap. +3.66%+0.44%+64.36%+115.84%
See all sector performances

Financials

2027 *2028 *
Net sales - 11.2M 7.97M 6.92M 6.45M 5.92M 758M 11.33M 76.02M 29.72M 379M 29.91M 29.26M 1.25B
Net income -248M -177M -153M -143M -131M -16.8B -251M -1.69B -659M -8.4B -663M -649M -27.83B -255M -182M -158M -147M -135M -17.27B -258M -1.73B -677M -8.63B -682M -667M -28.61B
Net Debt -436M -310M -269M -251M -231M -29.49B -441M -2.96B -1.16B -14.74B -1.16B -1.14B -48.85B -596M -424M -368M -343M -315M -40.29B -602M -4.04B -1.58B -20.14B -1.59B -1.56B -66.74B
* Estimated data More financial data

Company Profile

Logo Cybin Inc.
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Employees
-
Sector
Biotechnology & Medical Research
More about the company

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
13.05CAD
Average target price
49.53CAD
Spread / Average Target
+279.43%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. HELP Stock
  4. CLXP.F Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong